FDA & Acella Pharmaceuticals: A Path Forward for Desiccated Thyroid Extract
Acella Pharmaceuticals, the manufacturer of NP Thyroid®, has expressed its appreciation for a recent FDA notice clarifying the agency’s commitment to maintaining patient access to desiccated thyroid extract (DTE) products. This comes after an initial notice in August 2025, and as manufacturers navigate the Biologics License Application (BLA) process for these animal-derived medications. Approximately 1.5 million patients rely on DTE, making continued access a critical concern.
The FDA’s Evolving Stance on DTE
The FDA’s recent statement signals a move towards a risk-based enforcement approach. Rather than an immediate halt to unapproved DTE products, the agency will prioritize enforcement against manufacturers failing to meet quality standards. This approach aims to balance patient needs with the demand for rigorous quality control as the industry transitions towards formal BLA approval.
The FDA plans to issue draft guidance outlining conditions for continued market access beyond August 2026, contingent on manufacturers pursuing FDA approval as biologics. This provides a pathway for continued availability whereas ensuring products meet necessary safety and efficacy benchmarks.
Acella’s Commitment to Innovation and Affordability
Art Deas, CEO of Alora Pharmaceuticals (Acella’s parent company), emphasized the company’s dedication to quality, care, and affordability. Acella is actively collaborating with the FDA, through its sister company Neuvosyn Laboratories, to pursue formal approval of a new DTE product – North Star – utilizing the same active ingredient as NP Thyroid®. Phase II clinical trial results for North Star were reported as positive in September 2025.
Deas stated the company’s intention to avoid a “biologics price tag” for its new DTE product, underscoring a commitment to accessible healthcare for the 1.5 million Americans who depend on these medications.
Understanding Hypothyroidism and the Role of DTE
Hypothyroidism, a condition where the thyroid gland doesn’t produce enough thyroid hormones, affects millions. Symptoms include fatigue, weight gain, depression, and cognitive difficulties. Thyroid hormones are vital for regulating metabolism, energy, heart function, and brain health. DTE provides a natural source of thyroid hormones, offering an alternative treatment option for some patients.
Recent Coverage Changes & Market Dynamics
As of April 1, 2026, CVS Caremark, a major pharmacy benefit manager, is removing DTE medications, including NP Thyroid®, from its standard drug list. This highlights the evolving landscape of insurance coverage and the potential challenges patients may face in accessing these medications.
FAQ: Desiccated Thyroid Extract & FDA Regulations
Q: What is desiccated thyroid extract (DTE)?
A: DTE is a medication derived from the thyroid glands of pigs, used to treat hypothyroidism.
Q: Why did the FDA issue notices to DTE manufacturers?
A: The FDA requires manufacturers of animal-derived medications to pursue a Biologics License Application (BLA) to ensure safety and efficacy.
Q: Will DTE still be available after August 2026?
A: The FDA will allow continued market access under certain conditions, contingent on manufacturers pursuing BLA approval.
Q: What is Acella Pharmaceuticals doing to address these changes?
A: Acella is collaborating with the FDA to gain approval for a new DTE product, North Star, and is committed to providing affordable access to these medications.
Q: Where can I identify more information about NP Thyroid®?
A: Visit npthyroid.com/pi for full prescribing information.
Did you know? The FDA is prioritizing enforcement against DTE manufacturers who do not meet quality standards, ensuring patient safety remains a top concern.
Pro Tip: Stay informed about your prescription drug coverage and discuss any concerns with your healthcare provider and pharmacist.
Have questions about DTE or the recent FDA updates? Share your thoughts in the comments below!
Related reading